In a 500 L double-ribbon mixer operating at 15 rpm with a 60–70% fill volume, dry blending of veterinary-grade ginseng stem and leaf total saponin granules into a swine grow-finish premix is executed stepwise to prevent segregation of the 80% w/w ginsenoside-standardized granular API. The granules are de-dusted and pre-sieved through an 80-mesh (177 μm) stainless steel screen before addition to a 10:1 carrier dilution of calcium carbonate or rice hull flour. The formulation addition ratio is 100–500 g of the granular API per metric ton of complete feed, equivalent to 0.01–0.05% w/w complete feed and 80–400 mg total ginsenosides/kg feed. Compliance falls under Regulation (EU) 2019/6 for veterinary medicinal premises where the product is registered as an oral powder; in feed-additive jurisdictions, the material is handled under Regulation (EC) No 1831/2003 Annex III and requires authorization or notification prior to placing on the market. Mixing homogeneity is validated by ISO 6497:2002 sampling from 10 points, with acceptance at ≤5.0% coefficient of variation for ginsenoside Re and Rb1 markers. The finished product is a free-flowing premix or microgranule with a bulk density of 60–70 g/100 mL, dosed into complete feed at 5–20 kg/t. Production bottlenecks observed on manufacturing lines include hygroscopic bridging in the discharge hopper at ambient RH above 60% and static adhesion to polyethylene liners; room RH is maintained at ≤55% and contact surfaces are specified as stainless steel with 2B finish. Sealed aluminum-laminated packaging with desiccant maintains loss on drying below 5.0% w/w during storage at 15–25°C.

Why does total ginsenoside content decline when steam pelleting broiler feeds?

Steam conditioning of broiler crumble at 75–85°C for 30–60 seconds induces a measurable loss of dammarane-type ginsenosides, particularly malonyl-ginsenoside Rb1 and Rg1, through hydrolytic cleavage at the C-20 sugar linkage. When the granular API is included before conditioning at 150–300 g/t complete feed, post-conditioning recovery data from a 5-tonne/hour pellet press typically show a 15–20% reduction in total ginsenoside peak area by HPLC; the formulation addition ratio is therefore corrected to 180–360 g/t when pre-pellet inclusion cannot be avoided. The preferred downstream process is post-pellet vacuum coating at 0.02–0.08% w/w using a single-shaft vacuum coater with a 0.6 m³ working volume, spray time of 8–12 minutes, and vacuum of -0.06 MPa; this limits thermal loss to ≤5.0%. The full manufacturing sequence includes preconditioning of a corn-soybean diet to 12–14% moisture at the conditioner outlet, compression through a 3.0 mm die at a temperature not exceeding 85°C, counterflow cooling to ambient +5°C, and then spraying the saponin dispersion onto the pellet surface. Compliance is anchored to Regulation (EU) 2017/625 for feed manufacturing controls, ISO 22000:2018 HACCP prerequisite programs, and the zootechnical additive category of Regulation (EC) No 1831/2003 Annex I where botanical feed additives are permitted. The finished product is a heat-stabilized, low-dust pellet or crumble with a water activity below 0.65 and a post-pellet recovery rate of ≥90.0% for total ginsenosides.

For reconstitution into broiler drinking water, a 60% lactose-carrier water-soluble granule is prepared at a working concentration of 0.05–0.10 g of formulated powder per litre, equivalent to 40–80 mg total ginsenosides/L. The downstream process begins with fluid-bed top-spray granulation of the saponin powder with an aqueous binder solution of 5% w/v povidone K30 and 2% w/v maltodextrin, using inlet air at 60–65°C, product temperature at 35–40°C, and final moisture at ≤3.0% w/w. Particles are passed through a 150 μm sieve and blended with 0.5% w/w fumed silica to prevent caking; the resulting powder has a D90 of ≤150 μm and a dispersibility time of ≤60 seconds in water at 25°C. For a 1000 L header tank, the addition rate is 50–100 g of formulated powder, with medication pump injection at a 1:100 stock solution to drinking water. Compliance in the European Union falls under Regulation (EU) 2019/6 where the water-soluble powder is registered as a veterinary medicinal product; otherwise, in feed-additive markets, the product must meet Regulation (EC) No 183/2005 Annex II hygiene requirements and be supported by HACCP verification. Water quality criteria are per USP ⟨1231⟩ for pH 5.0–7.0, total hardness ≤300 mg/L CaCO₃, and free chlorine <2 ppm before reconstitution. The finished product is a 100 g or 500 g sealed sachet or 5 kg plastic jar of water-soluble powder, sized for 500–1000 broiler dose units; hard water above 300 mg/L CaCO₃ reduces ginsenoside solubility via divalent-cation complexation and is mitigated with a 0.1% w/v citric acid buffer.

Injectable aqueous formulations and the saponin aggregation boundary

Parenteral delivery of ginseng stem and leaf total saponin granules requires conversion into a sterile aqueous solution containing 5–20 mg/mL total ginsenosides, with sodium chloride or dextrose adjusted to 280–310 mOsm/kg and pH maintained between 5.5 and 6.5. Dammarane-series saponins possess a hydrophobic triterpene core and two sugar moieties, making them surface-active; below pH 4.5 or above pH 7.5, aggregation into colloidal micelles exceeds 200 nm and causes sterilizing-filter blinding. The downstream production process therefore avoids terminal autoclaving above 121°C because hydrolysis of the C-17 glycosidic bond reduces Rg1 content by 10–15% per 15-minute exposure at 121°C; instead, sterile filtration through a 0.22 μm PVDF filter in a 316L stainless steel vessel with nitrogen overlay is used, followed by aseptic filling into Type I glass vials. The formulation addition ratio for a 100 L batch is 0.5–2.0 kg of granular API, pre-dissolved in water for injection at 35–40°C with 0.5% w/v Tween 80 where the marketing authorization permits; without surfactant, loading is capped at 10 mg/mL to avoid precipitation during storage at 2–8°C. Compliance requires EU GMP Annex 1 for sterile medicinal products, USP ⟨1⟩ Injections, USP ⟨788⟩ Particulate Matter in Injections with limits of ≤6000 particles ≥10 μm and ≤600 particles ≥25 μm per container, USP ⟨85⟩ Bacterial Endotoxins with a limit of ≤0.5 EU/mg for parenteral APIs, and VICH GL18(R2) residual solvent testing. The finished product is a 10 mL or 50 mL single-dose or multi-dose vial with a 24-hour in-use stability period after first puncture; published data for ginseng total saponin injections in target animal species is limited, and any target-animal safety claim must be derived from the corresponding marketing-authorization file.

In transition dairy cattle tablets, the granular API is wet granulated with 5% w/v povidone K30 in a high-shear granulator at impeller speed 150–200 rpm and chopper speed 3000 rpm, then fluid-bed dried at 60°C to 2.0–3.5% w/w loss on drying and compressed on a rotary press at 10–25 kN into 2.0 g oral tablets. Each tablet contains 200–400 mg total ginsenosides (10–20% w/w API) together with dicalcium phosphate dihydrate, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate at 0.5% w/w. Compliance is under Regulation (EU) 2019/6, Directive 91/412/EEC GMP principles for veterinary medicinal products, and VICH GL18(R2) residual solvents; friability is tested per USP ⟨1216⟩ at ≤1.0% and disintegration per USP ⟨701⟩ at ≤30 minutes in 0.1 N HCl at 37°C. The finished product is a 2.0 g bisect tablet in aluminum/aluminum blister packs under nitrogen to protect the hygroscopic saponin.

Aquafeed extrusion survival is not a single-factor problem

Ginseng stem and leaf total saponin granules incorporated into sinking aquafeed for tilapia or carp are severely degraded by extrusion cooking at 120–140°C; the combined effects of moisture, shear, and pressure hydrolyze ginsenoside Rb1 to rare sapogenins with a loss of 25–35% when included pre-extrusion. Consequently, the addition ratio is recalculated for post-extrusion coating: 200–500 g of the granular API per metric ton of finished aquafeed is applied through a vacuum coater operated at -0.04 to -0.08 MPa for 10–15 minutes, using a 35–40% w/w fat or oil carrier. The downstream production process begins with twin-screw extrusion of a fishmeal-soybean meal blend at a specific mechanical energy of 25–35 kWh/t, die temperature of 120–140°C, and steam pre-conditioner moisture of 18–22%; the extruded pellet is dried to 8–10% moisture, cooled, and then coated with the saponin dispersion in a rotating vacuum coater to a final surface oil content of 5–8% w/w. Compliance includes ISO 22000:2018, Codex Alimentarius CXC 1-1969 Rev. 2020 for HACCP, and national aquatic animal health registration where the product is classified as an immunostimulant feed additive; residual solvent and elemental impurity testing follows USP ⟨232⟩/⟨233⟩. The finished product is a 2.0–4.0 mm sinking pellet or a 1.5–2.5 mm extruded crumble with water stability of ≥120 minutes in water at 28°C and a total ginsenoside recovery of ≥90.0% on the pellet surface.

For companion animal oral capsules, the milled granular API is filled at 100–250 mg into size 1 HPMC capsules using a dosator-type machine at 60–80 capsules/min; the direct blend contains lactose or microcrystalline cellulose and 0.5% w/w magnesium stearate. Weight variation is controlled per USP ⟨905⟩ at ±5% for a 250 mg fill weight, and microbial limits follow USP ⟨61⟩/⟨62⟩ with absence of E. coli. Compliance is under Regulation (EU) 2019/6 or Regulation (EC) No 767/2009 depending on the registration pathway. The finished product is a 100-capsule HDPE bottle with a desiccant canister, labeled for canine or feline oral administration.